Registry following people with multiple myeloma through routine care
Records disease features, treatment and outcomes in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Myeloma Registry Platform (MYRIAM)
Key facts
- Where
- Multiple Sites, GermanySee the site
Where in Germany
- Multiple sites all over germanyMultiple Sites, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT03308474
- Record updated
- 13 July 2026
- Original description
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.Read full original descriptionShow less
Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.
Inclusion: MM requiring systemic (first-, second- or third-line) treatment (closed for first-line / second-line recruitment); Age ≥ 18 years; Written informed consent; Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment; Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment; Sufficient German language skills for participation in the PRO satellite.
Exclusion: No systemic therapy for myeloma; Patients already enrolled in studies that prohibit any participation in other studies.